soft tissue sarcoma

soft tissue sarcoma
ThatPeskyCommoner · CC BY-SA 3.0 · source
Name	Soft tissue sarcoma
Field	Oncology, Pathology

soft tissue sarcoma

Soft tissue sarcoma is a heterogeneous group of mesenchymal malignancies arising in skeletal muscle, adipose, fibrous, vascular, or peripheral nerve–associated tissues. Typically presenting as a painless mass, these tumors require multidisciplinary management involving surgical oncology, medical oncology, radiation oncology, radiology, and pathology teams. Historically influenced by work at institutions such as Memorial Sloan Kettering Cancer Center, Mayo Clinic, Johns Hopkins Hospital, and MD Anderson Cancer Center, contemporary care integrates advances from clinical trials sponsored by groups like the European Organisation for Research and Treatment of Cancer and the National Cancer Institute.

Introduction

Soft tissue sarcomas encompass over 70 histologic subtypes defined by distinct clinical behavior and biology, a diversity recognized in classification systems developed by the World Health Organization and refined after meetings at the American Society of Clinical Oncology and the International Agency for Research on Cancer. Epidemiologic patterns documented by agencies such as the Surveillance, Epidemiology, and End Results Program and studies from centers like Stanford University show variable incidence across populations studied in United States, United Kingdom, France, Japan, and Australia.

Signs and symptoms

Patients commonly report a progressively enlarging, firm, painless mass often mistaken for benign entities seen by providers at Mayo Clinic or in community settings referenced by NHS (England). Symptoms depend on anatomic site, with tumors in the retroperitoneum producing vague abdominal fullness similar to cases treated at Cleveland Clinic, while lesions near neurovascular bundles reported in series from Massachusetts General Hospital may cause pain, paresthesia, or limb dysfunction leading to referrals to Royal Marsden Hospital or Karolinska University Hospital. Systemic features such as weight loss or fever are less common but have been described in case series published by investigators at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.

Pathology and classification

Histologic diagnosis relies on morphologic assessment and immunohistochemistry performed in laboratories associated with American Board of Pathology standards and published atlases from the World Health Organization. Frequent subtypes include liposarcoma, leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor, and undifferentiated pleomorphic sarcoma—entities delineated in monographs from Oxford University Press and consensus statements from the International Society of Paediatric Oncology. Molecular signatures such as translocations (e.g., SS18-SSX in synovial sarcoma) were characterized in landmark publications from research groups at Harvard Medical School, University of California, San Francisco, and Cold Spring Harbor Laboratory.

Diagnosis and staging

Diagnosis is established by core needle biopsy often performed by interventional radiology teams at centers like Brigham and Women's Hospital with staging using cross-sectional imaging including MRI protocols standardized by radiology societies and PET/CT modalities available at facilities including Memorial Sloan Kettering Cancer Center and Stanford University Medical Center. Staging follows systems promulgated by the American Joint Committee on Cancer and informed by trials from cooperative groups such as the Children's Oncology Group for pediatric cases; staging determines surgical planning similar to approaches developed at MD Anderson Cancer Center.

Treatment

Local control typically requires wide surgical resection coordinated by surgical oncologists trained at institutions like Johns Hopkins Hospital and augmented by radiotherapy protocols from Royal Marsden Hospital and Institute Gustave Roussy. For high-risk or metastatic disease, systemic therapy includes conventional cytotoxic regimens reported by European Society for Medical Oncology and novel targeted agents evaluated in trials run by the National Cancer Institute and pharmaceutical collaborations involving companies such as Pfizer and Novartis. Limb-sparing surgery with reconstructive input from teams at Mount Sinai Health System is preferred over amputation except in select cases, guided by outcomes analyses from Memorial Sloan Kettering Cancer Center and Mayo Clinic.

Prognosis and epidemiology

Prognosis varies by subtype, grade, size, and resectability; long-term outcome data derive from population registries maintained by organizations like Surveillance, Epidemiology, and End Results Program and institutional series from MD Anderson Cancer Center and Royal Marsden Hospital. Five-year survival differs markedly—for example, well-differentiated liposarcoma cohorts reported by Mayo Clinic show favorable outcomes compared with aggressive leiomyosarcoma series analyzed at Dana-Farber Cancer Institute. Incidence peaks in middle-aged and older adults in datasets compiled by the Centers for Disease Control and Prevention and exhibits pediatric patterns documented by the Children's Oncology Group.

Research and molecular genetics

Translational research employs genomic platforms developed at Broad Institute, Wellcome Sanger Institute, and National Cancer Institute to characterize copy-number alterations, fusion oncogenes, and actionable mutations; prominent findings published from consortia including The Cancer Genome Atlas and collaborations with European Organisation for Research and Treatment of Cancer have informed targeted drug development programs at companies like AstraZeneca and Roche. Emerging approaches include immunotherapy trials led by investigators at Memorial Sloan Kettering Cancer Center, adoptive cell therapies pioneered at National Institutes of Health, and precision oncology initiatives coordinated through networks such as ASCO and European Society for Medical Oncology.

Category:Cancer